Emergent BioSolutions | EBS - Operating Profit


Emergent BioSolutions reported $-218M in Operating Profit for its fiscal quarter ending in June of 2023.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Exelixis USD 251.34M 15.43M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Lonza CHF 673M 243M Jun/2025
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Xoma USD -15.64M 5.56M Sep/2024